(Q35558793)

8 August 2017

1 reference

title

C-reactive protein: a surrogate risk marker or mediator of atherothrombosis? (English)

1 reference

8 August 2017

1 reference

https://api.crossref.org/works/10.1152/AJPREGU.00227.2003

21 March 2024

2

Paul M Ridker

1 reference

8 August 2017

Gavin J. Blake

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14557240

21 March 2024

Paul M. Ridker

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14557240

21 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14557240

21 March 2024

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

http://intl-ajpregu.physiology.org/cgi/content/abstract/285/5/R1250

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14557240

https://www.physiology.org/doi/pdf/10.1152/ajpregu.00227.2003

21 March 2024

1 reference

https://api.crossref.org/works/10.1152/AJPREGU.00227.2003

American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

21 March 2024

published in

1 reference

8 August 2017

285

1 reference

8 August 2017

5

1 reference

8 August 2017

R1250-2

1 reference

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

8 August 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Novel clinical markers of vascular wall inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Generation of C-reactive protein and complement components in atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00227.2003

Direct proinflammatory effect of C-reactive protein on human endothelial cells

21 January 2018

12

1 reference

https://api.crossref.org/works/10.1152/AJPREGU.00227.2003

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

21 March 2024

20

1 reference

https://api.crossref.org/works/10.1152/AJPREGU.00227.2003

C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries

21 March 2024

25

1 reference

https://api.crossref.org/works/10.1152/AJPREGU.00227.2003

Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells

21 March 2024

26

1 reference

https://api.crossref.org/works/10.1152/AJPREGU.00227.2003

21 March 2024

Identifiers

1 reference

8 August 2017

1 reference